EZH2 and diffuse intrinsic pontine glioma: We also recently demonstrated preclinical efficacy of BET/Bromodomain inhibition for DIPG treatment, while Mohammad and colleagues showed that inhibition of EZH2, the enzymatic subunit of PRC2 that catalyzes H3K27 trimethylation (H3K27me3), may also be an effective therapeutic strategy for treating H3K27M DIPG [3].